Evidence map›Paper›PMID 41079669›Full record

ReviewResearch (Washington, D.C.)2025

Epigenetic Regulation of Ferroptosis in Chronic Kidney Disease: Mechanisms and Implications.

Zi-Hui Mao, Yong Liu, Qing Zhang, Shaokang Pan, Duo Chen, Yingjin Qiao, Hui Wang, Dongwei Liu, Zhangsuo Liu, Qi Feng

Abstract readReview
In one paragraph

Review in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Mitochondrial function meets oncology: the multifaceted role of TFAM across cancer types.Apoptosis : an international journal on programmed cell death · 2026
    Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zi-Hui MaoDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450052, P. R. China.
Yong LiuDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450052, P. R. China.
Qing ZhangDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450052, P. R. China.
Shaokang PanDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450052, P. R. China.
Duo ChenDepartment of Endocrinology and Metabolism, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, P. R. China.
Yingjin QiaoBlood Purification Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, P. R. China.
Hui WangDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450052, P. R. China.
Dongwei LiuDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450052, P. R. China.
Zhangsuo LiuDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450052, P. R. China.
Qi FengDepartment of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450052, P. R. China.ORCID https://orcid.org/0000-0001-8724-5710

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) is a prevalent and progressive condition that leads to renal structural abnormalities and a gradual decline in kidney function. CKD has various etiologies, including diabetes, hypertension, and glomerulonephritis, and is associated with significant morbidity, mortality, and economic burden. Current treatments focus on slowing disease progression and managing complications; however, CKD often progresses to end-stage renal disease, necessitating renal replacement therapy. Therefore, innovative therapeutic approaches are urgently required. Recent studies have highlighted the role of ferroptosis, an iron-dependent form of cell death characterized by lipid peroxidation and oxidative stress, in CKD pathogenesis. Ferroptosis contributes to structural damage and functional impairment in renal cells. Furthermore, epigenetic modifications, including DNA methylation and histone changes, regulate gene expression without altering the DNA sequence and have been implicated in CKD progression. These epigenetic alterations may influence inflammation, fibrosis, and ferroptosis, thereby exacerbating renal dysfunction. This review explores the intersection of ferroptosis and epigenetic regulation in CKD, offering novel insights into the mechanisms driving disease progression and potential therapeutic targets. Through a comprehensive bibliometric analysis, this study provides a deeper understanding of CKD pathogenesis and proposes potential future treatment strategies.

Identifiers

PMID41079669
PMCPMC12508529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.